CELZ - Latest News
Creative Medical Technology Holdings, Inc. (CELZ), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $2.9M. Beta to the broader market is 1.94.
The article list below shows the most recent CELZ headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent CELZ Headlines
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
globenewswire.com - Aug 20, 2026
All patients enrolled and treated across original and FDA-cleared expansion cohorts Positive safety and early efficacy signals continue to support lat
Creative Medical Technology Stock Surges After Key Patent Win
benzinga.com - Aug 6, 2026
Creative Medical Technology Holdings Inc. (NASDAQ:CELZ) shares are surging Thursday afternoon following an intellectual property milestone.
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
globenewswire.com - Aug 6, 2026
Newly Allowed Patent Protects Cell-Free MyeloCelz™ Exosome Technology Designed to Suppress Autoimmune Destruction of Insulin-Producing Cells, Reinforc
Creative Medical Technology Holdings Issues Mid-Year Update
globenewswire.com - Jul 1, 2026
Highlights Significant Clinical, Regulatory, and Strategic Progress, Supported by a Disciplined Capital Allocation Strategy Highlights Significant Cli
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
globenewswire.com - Jun 30, 2026
PHOENIX, June 30, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. , (Nasdaq: CELZ) (the “Company”), a biotechnology company dedica
How News Affects CELZ Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track CELZ's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked CELZ news questions
- What is the latest CELZ news headline?
- The most recent CELZ headline (Aug 20, 2026) is "Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the CELZ news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What CELZ news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual CELZ options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.